title: Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic.
abstract: METHODS
  An Australian metropolitan TB clinic where treatment for latent tuberculosis infection (LTBI) comprises six months of isoniazid, self-administered but dispensed monthly by the clinic.
  
  
  OBJECTIVE
  To determine the proportion of patients who complete treatment for LTBI and to identify factors associated with non-completion.
  
  
  METHODS
  Clinical files of all patients receiving treatment for LTBI between 01/2000 and 12/2010 were reviewed. The study population comprised all patients who were commenced on isoniazid as treatment for LTBI. Odds ratios (OR) for completing treatment were estimated by logistic regression.
  
  
  RESULTS
  Of 216 patients who commenced isoniazid treatment for LTBI, 163 (75%) completed six months treatment [corrected]. Fifty-three percent of the 53 patients who did not complete treatment dropped out after three months treatment. The mean (SD) age of the patients was 27 (16) years and 123 (57%) were female. The majority of patients (59%) were born overseas and 69% received treatment for LTBI because they were contacts of patients with TB. Patients' sex, age, country of birth, time since immigration for overseas born people, health care worker status, TST conversion status, chest x-ray findings, language, employment status and the indication for which treatment of LTBI was prescribed were not significantly related to treatment completion.
  
  
  CONCLUSIONS
  In a setting where isoniazid is dispensed monthly by the TB clinic, a relatively high proportion of patients who commence treatment for LTBI complete the six month scheduled course of treatment. The study did not identify any patient characteristics that predicted treatment completion. Interventions to improve completion rates should extend over the whole duration of treatment.
authors.affiliation: Respiratory and Environmental Epidemiology, Woolcock Institute of Medical Research and Central Clinical School, University of Sydney, Sydney, Australia. cdobler@med.usyd.edu.au
authors.forename: Claudia C
authors.initials: CC
authors.lastname: Dobler
authors.forename: Guy B
authors.initials: GB
authors.lastname: Marks
mesh_terms: D000328:Adult; D000554:Ambulatory Care Facilities; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001315:Australia; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use*; D055985:Latent Tuberculosis / Q000188:drug therapy*; D008297:Male; D010594:Pharmacies; D016896:Treatment Outcome
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid